Scarica l'app Stockscreener
1.04
0.00%
0.00
Dopo l'orario di chiusura:
1.02
-0.02
-1.92%
Precedente Chiudi:
$1.04
Aprire:
$1.04
Volume 24 ore:
102.27K
Relative Volume:
0.37
Capitalizzazione di mercato:
$47.29M
Reddito:
-
Utile/perdita netta:
$-31.39M
Rapporto P/E:
-1.2381
EPS:
-0.84
Flusso di cassa netto:
$-18.45M
1 W Prestazione:
-6.31%
1M Prestazione:
-7.96%
6M Prestazione:
-49.27%
1 anno Prestazione:
+24.95%
Intervallo 1D:
$1.01
$1.05
Intervallo di 1 settimana:
$0.925
$1.1365
Portata 52W:
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Nome
Quince Therapeutics Inc
Settore
Industria
Telefono
415-910-5717
Indirizzo
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Confronta QNCX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.04 | 50.47M | 0 | -31.39M | -18.45M | -0.84 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-24 | Iniziato | Oppenheimer | Outperform |
Quince Therapeutics Inc Borsa (QNCX) Ultime notizie
Finch Therapeutics Group (NASDAQ:FNCH) and Quince Therapeutics (NASDAQ:QNCX) Head to Head Comparison - Defense World
Brookline Capital Management Forecasts QNCX Q2 Earnings - Defense World
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026 (NASDAQ:QNCX) - Seeking Alpha
Quince Therapeutics Reports Q1 2025 Results and Strategic Updates - TipRanks
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - BioSpace
Quince Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Quince Therapeutics, Inc. SEC 10-Q Report - TradingView
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results | QNCX Stock News - GuruFocus
Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Quince Therapeutics (QNCX) CEO to Present at Life Sciences Confe - GuruFocus
Quince Therapeutics (QNCX) CEO to Present at Life Sciences Conference - GuruFocus
Geode Capital Management LLC Has $703,000 Position in Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics to Present at Citizens Life Sciences Conference - BioSpace
Quince Therapeutics Inc (QNCX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Ratios Uncovered: Breaking Down Quince Therapeutics Inc (QNCX)’s Trailing Twelve Months Metrics - DWinneX
Closing Figures Unveiled: Quince Therapeutics Inc (QNCX) Drop -8.93, Closes at 1.02 - DWinneX
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Buy” by Analysts - Defense World
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference - BioSpace
Rare Disease Biotech Quince to Unveil Latest Developments at Major Healthcare Conference - Stock Titan
Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
D. Boral Capital Issues Pessimistic Forecast for Quince Therapeutics (NASDAQ:QNCX) Stock Price - The AM Reporter
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Quince Therapeutics (NASDAQ:QNCX) Price Target Lowered to $4.00 at D. Boral Capital - Defense World
Quince Therapeutics Reports 2024 Financial Results and Trial Progress - TipRanks
Quince Therapeutics stock target cut to $4 from $12, maintains buy By Investing.com - Investing.com South Africa
Quince Therapeutics stock target cut to $4 from $12, maintains buy - Investing.com
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Oppenheimer - Defense World
Quince Therapeutics Existing Cash Position To Provide Operating Runway Through Phase 3 Topline Results Into 2026 - MarketScreener
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
Oppenheimer sets $10 target for Quince Therapeutics stock By Investing.com - Investing.com South Africa
Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Quince Therapeutics at Outperform -March 24, 2025 at 07:46 am EDT - Marketscreener.com
Oppenheimer sets $10 target for Quince Therapeutics stock - Investing.com
Quince Therapeutics Files For Common Stock Offering Of Up To $21.9 MillionSEC Filing - marketscreener.com
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of “Buy” by Analysts - The AM Reporter
Quince Therapeutics (QNCX) Projected to Post Earnings on Monday - Defense World
Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $9.50 - Defense World
Quince Therapeutics (NASDAQ:QNCX) versus IN8bio (NASDAQ:INAB) Critical Contrast - Defense World
Market Momentum Report: Quince Therapeutics Inc (QNCX)’s Negative Close at 1.41 - The Dwinnex
Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms - Fierce Biotech
Vaxart (NASDAQ:VXRT) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Comparison - Armenian Reporter
Ataxia Treatment Market Size in the 7MM is expected to grow - openPR
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
Head to Head Comparison: Quince Therapeutics (NASDAQ:QNCX) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Spotlight On Fractyl Health And Two Other Intriguing Penny Stocks - Simply Wall St
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average Price Target from Analysts - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Quince Therapeutics Inc Azioni (QNCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):